Drug
BI Sifrol
BI Sifrol: highest development phase Post-Market, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI-Sifrol® NCT02231905 | Post-Market | Parkinson Disease |
Latest
No recent events.
Follow BI Sifrol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.